NCT05600686View on ClinicalTrials.gov

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2028

Conditions
Double-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Loncastuximab Tesirine

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine

Given IV

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

ADC Therapeutics S.A.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

ADC Therapeutics S.A.

INDUSTRY

lead

Joseph Tuscano

OTHER